Ser49
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser49  -  RXRA (human)

Site Information
GSPGQLHsPISTLSS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 333674901

In vivo Characterization
Methods used to characterize site in vivo:
flow cytometry ( 2 ) , immunoprecipitation ( 2 ) , mutation of modification site ( 1 , 2 ) , phospho-antibody ( 2 ) , western blotting ( 1 , 2 )
Disease tissue studied:
breast cancer ( 1 ) , breast adenocarcinoma ( 1 ) , breast cancer, triple negative ( 1 ) , colorectal cancer ( 2 ) , colorectal carcinoma ( 2 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 2 ) , HCT116 (intestinal) ( 2 ) , MDA-MB-231 (breast cell) ( 1 ) , MDA-MB-468 (breast cell) ( 1 ) , SW480 (intestinal) ( 2 )

Upstream Regulation
Regulatory protein:
DANCR (human) ( 1 )
Putative in vivo kinases:
GSK3B (human) ( 1 , 2 )

Downstream Regulation
Effects of modification on RXRA:
ubiquitination ( 2 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , signaling pathway regulation ( 1 ) , transcription, induced ( 1 )

References 

1

Tang J, et al. (2018) LncRNA DANCR upregulates PI3K/AKT signaling through activating serine phosphorylation of RXRA. Cell Death Dis 9, 1167
30518934   Curated Info

2

Liang J, et al. (2017) miR-27a-3p targeting RXRα promotes colorectal cancer progression by activating Wnt/β-catenin pathway. Oncotarget 8, 82991-83008
29137318   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.